Phase III Study Comparing SHR-8068 with Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab with Bevacizumab for First-Line Treatment of Advanced Hepatocellular Carcinoma

What this Trial Is About

Researchers are evaluating the effectiveness of SHR-8068 combined with Adebrelimab and Bevacizumab compared with Sintilimab or Atezolizumab combined with Bevacizumab as first-line treatments for advanced hepatocellular carcinoma HCC. This phase III clinical trial focuses on patients with unresectable locally advanced or metastatic HCC, aiming to understand how these drug combinations perform in managing this serious liver cancer. Participants receive intravenous infusions of study drugs according to their assigned group. One group receives SHR-8068, Adebrelimab, and Bevacizumab, while the other group receives either Sintilimab combined with Bevacizumab or Atezolizumab combined with Bevacizumab. The study is randomized and open-label, meaning patients are randomly assigned to a treatment group and both patients and researchers know which treatment is given. Treatments are delivered by injection in cycles as per the study protocol. During the study, participants undergo regular assessments to monitor disease progression and treatment effects, including imaging evaluations based on RECIST v1.1 criteria reviewed by an independent committee. Researchers measure progression-free survival, overall survival, response rates, duration of response, and adverse events up to approximately 36 months. Participants are closely monitored for safety throughout the study, with follow-up visits to evaluate ongoing effects and health status.

A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma